LVCLF (Algorae Pharmaceuticals) Research & Development : $0.15 Mil (TTM As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Algorae Pharmaceuticals Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Algorae Pharmaceuticals's Research & Development for the six months ended in Dec. 2023 was $0.27 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $0.15 Mil.

Algorae Pharmaceuticals Research & Development Historical Data

The historical data trend for Algorae Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Research & Development Chart

Algorae Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Research & Development

Get a 7-Day Free Trial

1.65

1.23

1.03

0.88

0.15

Algorae Pharmaceuticals Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Research & Development	Get a 7-Day Free Trial															0.60	0.63	0.25	0.27	-0.12

Algorae Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.15 Mil.

Algorae Pharmaceuticals (OTCPK:LVCLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Algorae Pharmaceuticals Research & Development Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Algorae Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (OTCPK:LVCLF) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

LHI0:Germany 1AI:Australia

Address

525 Collins Street, Level 23, Rialto South Tower, Melbourne, VIC, AUS, 3000

Website

https://www.algoraepharma.com

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals Headlines

From GuruFocus

Living Cell Technologies Ltd at Vertical Events Gold Coast Investment Showcase Transcript

By GuruFocus Research • 02-14-2024